Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.
Scheiner B, Kang B, Balcar L, Radu IP, Reiter FP, Adžić G, Guo J, Gao X, Yuan X, Cheng L, Gorgulho J, Schultheiss M, Peeters F, Hucke F, Ben Khaled N, Piseddu I, Philipp A, Sinner F, D'Alessio A, Pomej K, Saborowski A, Bathon M, Schwacha-Eipper B, Zarka V, Lampichler K, Nishida N, Lee PC, Krall A, Saeed A, Himmelsbach V, Tesini G, Huang YH, Vivaldi C, Masi G, Vogel A, Schulze K, Trauner M, Djanani A, Stauber R, Kudo M, Parikh ND, Dufour JF, Prejac J, Geier A, Bengsch B, von Felden J, Venerito M, Weinmann A, Peck-Radosavljevic M, Finkelmeier F, Dekervel J, Ji F, Wang HW, Rimassa L, Pinato DJ, Bouattour M, Chon HJ, Pinter M. Scheiner B, et al. Among authors: piseddu i. Hepatology. 2024 Nov 21. doi: 10.1097/HEP.0000000000001163. Online ahead of print. Hepatology. 2024. PMID: 39643944
Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study.
Ertl C, Ruf T, Hammann L, Piseddu I, Wang Y, Schmitt C, Garza Vazquez X, Kabakci C, Bonczkowitz P, de Toni EN, David-Rus R, Srour J, Tomsitz D, French LE, Heinzerling L. Ertl C, et al. Among authors: piseddu i. Eur J Cancer. 2024 Nov;212:115049. doi: 10.1016/j.ejca.2024.115049. Epub 2024 Sep 27. Eur J Cancer. 2024. PMID: 39383612 Free article.
Immune Modulation in Untreated, Contralateral Hepatic Metastases after Yttrium-90 Radioembolization of Microsatellite Stable Colorectal Cancer.
Öcal E, Alunni-Fabbroni M, Piseddu I, Thaler M, Zacherl MJ, Salvermoser L, Stechele MMR, Burnell LF, Hirner-Eppeneder H, Kimm MA, Rudelius M, Seidensticker M, Wildgruber M, Goldberg SN, Ricke J. Öcal E, et al. Among authors: piseddu i. J Vasc Interv Radiol. 2024 Dec;35(12):1793-1805.e4. doi: 10.1016/j.jvir.2024.07.010. Epub 2024 Jul 22. J Vasc Interv Radiol. 2024. PMID: 39047935 Free article.
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.
Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, Anz D, Piseddu I, Pesch G, Vera J, Froehlich W, Weckbach L, Tomsitz D, Loquai C, Zimmer L, Mangana J, Dummer R, Gutzmer R, Klespe KC, Stege H, Meiss F, Thoms KM, Terheyden P, Bröckelmann PJ, Johnson DB, French LE, Heinzerling L. Wang Y, et al. Among authors: piseddu i. Front Cardiovasc Med. 2024 Jun 10;11:1408586. doi: 10.3389/fcvm.2024.1408586. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38915743 Free PMC article.
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N, Möller M, Jochheim LS, Leyh C, Ehmer U, Böttcher K, Pinter M, Balcar L, Scheiner B, Weich A, Leicht HB, Zarka V, Ye L, Schneider J, Piseddu I, Öcal O, Rau M, Sinner F, Venerito M, Gairing SJ, Förster F, Mayerle J, De Toni EN, Geier A, Reiter FP. Ben Khaled N, et al. Among authors: piseddu i. JHEP Rep. 2024 Apr 8;6(6):101065. doi: 10.1016/j.jhepr.2024.101065. eCollection 2024 Jun. JHEP Rep. 2024. PMID: 38798717 Free PMC article.
Lysosomal endonuclease RNase T2 and PLD exonucleases cooperatively generate RNA ligands for TLR7 activation.
Bérouti M, Lammens K, Heiss M, Hansbauer L, Bauernfried S, Stöckl J, Pinci F, Piseddu I, Greulich W, Wang M, Jung C, Fröhlich T, Carell T, Hopfner KP, Hornung V. Bérouti M, et al. Among authors: piseddu i. Immunity. 2024 Jul 9;57(7):1482-1496.e8. doi: 10.1016/j.immuni.2024.04.010. Epub 2024 May 1. Immunity. 2024. PMID: 38697119 Free PMC article.
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela MR, Gevers TJG, Beretta-Piccoli BT, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K. Kocheise L, et al. Among authors: piseddu i. Front Immunol. 2024 Jan 24;15:1369747. doi: 10.3389/fimmu.2024.1369747. eCollection 2024. Front Immunol. 2024. PMID: 38327519 Free PMC article.
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.
Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. Märkl F, et al. Among authors: piseddu i. Nat Commun. 2024 Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. Nat Commun. 2024. PMID: 38307904 Free PMC article.
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K. Kocheise L, et al. Among authors: piseddu i. Front Immunol. 2024 Jan 10;14:1326078. doi: 10.3389/fimmu.2023.1326078. eCollection 2023. Front Immunol. 2024. PMID: 38268921 Free PMC article.
Concomitant Irradiation to Checkpoint Inhibitor Therapy of Hepatocellular Carcinoma Patients: A Systematic Retrospective, Single-Center Analysis.
Munker S, Roessler D, Öcal O, Ben-Khaled N, Bernhart K, Ye L, Piseddu I, Vielhauer J, Reiter FP, Rodriguez I, Ricke J, Teufel A, De Toni E, Seidensticker M, Niyazi M, Corradini S. Munker S, et al. Among authors: piseddu i. Oncol Res Treat. 2023;46(11):466-475. doi: 10.1159/000533983. Epub 2023 Oct 12. Oncol Res Treat. 2023. PMID: 37827135 Free PMC article.
17 results